Ademi LLP is investigating AtaiBeckley (Nasdaq: ATAI) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Eli Lilly.
AtaiBeckley shareholders will receive $6.75 per share at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley’s two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion.
AtaiBeckley insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for AtaiBeckley by imposing a significant penalty if AtaiBeckley accepts a competing bid. We are investigating the conduct of the AtaiBeckley board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
Join this Action